Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

Rhea-AI Summary

Marinus Pharmaceuticals (MRNS) plans to release its second-quarter financial results for the period ending June 30, 2022, before U.S. market open on August 11, 2022. The company will host a conference call at 8:30 a.m. ET the same day. Marinus is focused on developing innovative therapeutics for seizure disorders, with its product ZTALMY (ganaxolone) approved for treating seizures associated with CDKL5 deficiency disorder. Ganaxolone is also under investigation for other conditions in Phase 3 trials.

Positive

• ZTALMY (ganaxolone) approved for CDKL5 deficiency disorder.
• Ongoing Phase 3 trials for ganaxolone in tuberous sclerosis complex and refractory status epilepticus.

Negative

• None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Time on August 11, 2022.

Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals

Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005199/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When will Marinus Pharmaceuticals release its Q2 financial results?

Marinus Pharmaceuticals will release its Q2 financial results on August 11, 2022.

What time is the Marinus Pharmaceuticals conference call?

The conference call will take place at 8:30 a.m. Eastern Time on August 11, 2022.

What is ZTALMY used for?

ZTALMY (ganaxolone) is approved for treating seizures associated with CDKL5 deficiency disorder.

What trials are ongoing for Marinus Pharmaceuticals?

Marinus is conducting Phase 3 trials for ganaxolone in tuberous sclerosis complex and refractory status epilepticus.